PRODUCT OVERVIEW & COMPOSITION
Brand / Manufacturer: Bioniche Pharma
Active Ingredient: Nandrolone Phenylpropionate (150 mg per ml)
Pharmacological Class: Synthetic Anabolic-Androgenic Steroid ($19\text{-nortestosterone}$ derivative / Short-acting Progestational Anabolic)
Bioniche Pharma Nandrolone Phenylpropionate 150 mg is a fast-acting injectable anabolic agent belonging to the $19\text{-nortestosterone}$ class. Formulated with a short phenylpropionate ester for rapid systemic release, Bioniche Pharma Nandrolone Phenylpropionate delivers strong anabolic properties and moderate androgenic activity, significantly enhancing intracellular protein synthesis and nitrogen retention.
CLINICAL PHARMACOLOGY & MECHANISM OF ACTION
Bioniche Pharma Nandrolone Phenylpropionate acts through high-affinity binding to nuclear androgen receptors in target tissues, shifting systemic nitrogen balance into a positive state to accelerate skeletal muscle repair and accretion. Owing to its $19\text{-nor}$ structure, Bioniche Pharma Nandrolone Phenylpropionate undergoes minimal aromatization to estrogen compared to native testosterone. However, it retains intrinsic affinity for progesterone receptors, requiring balanced therapeutic management.
INDICATIONS & CLINICAL USE
- Therapeutic recovery and tissue rebuilding in patients recovering from severe catabolic states, chronic debilitating conditions, or major surgical interventions with Bioniche Pharma products.
- Adjunctive treatment for specific non-responsive anemias and bone density preservation under strict Bioniche Pharma therapeutic supervision.
CONTRAINDICATIONS
- Male patients with confirmed or suspected carcinoma of the prostate gland or male breast cancer.
- Pregnancy, suspected pregnancy, and lactation due to severe risks of fetal masculinization and developmental toxicity.
- Patients with a documented history of hypersensitivity to Bioniche Pharma Nandrolone Phenylpropionate, carrier oils, or inactive excipients in Bioniche Pharma injectables.
PRECAUTIONS & CLINICAL MONITORS
- Virilization Risk in Females: Female patients administered Bioniche Pharma Nandrolone Phenylpropionate must be closely monitored for virilization signs, including deepening of the voice (dysphonia), hirsutism, acne, clitoromegaly, and menstrual irregularities. Treatment should be discontinued if early virilizing symptoms occur.
- Cardiovascular & Lipid Monitoring: Exogenous androgens and $19\text{-nor}$ steroids can reduce serum HDL cholesterol while elevating LDL cholesterol during Bioniche Pharma therapy. Caution is warranted in patients with a history of myocardial infarction or coronary artery disease. Periodic lipid panel evaluations are strongly advised.
- Systemic Observations: Monitor Bioniche Pharma patients for nausea, emesis, changes in skin pigmentation, peripheral edema (ankle swelling), acne vulgaris, gynecomastia, and changes in behavior or aggression.
ADVERSE REACTIONS
- Endocrine & Reproductive: Reversible suppression of the hypothalamic-pituitary-gonadal (HPG) axis, potential gynecomastia due to progestational activity, and altered serum prolactin levels associated with Bioniche Pharma administration.
- Dermatological & Androgenic: Increased sebaceous gland activity, acne, oily skin, hair thinning, and increased libido. Higher dosages of Bioniche Pharma formulations significantly elevate virilization risks in females.
- Cardiovascular & Hematological: Mild fluid and sodium retention leading to potential blood pressure increases; periodic complete blood count (CBC) monitoring is recommended during Bioniche Pharma treatment.
DOSAGE & ADMINISTRATION
Bioniche Pharma Nandrolone Phenylpropionate is administered via intramuscular injection. Due to the short half-life of the phenylpropionate ester, Bioniche Pharma injections are typically divided and administered 2 to 3 times per week as directed by a qualified physician:
- Adult Males: Typical therapeutic administration of Bioniche Pharma Nandrolone Phenylpropionate totals between 300 mg and 600 mg per week.
- Adult Females: When clinically indicated, responses to Bioniche Pharma therapy are generally observed at 50 mg to 100 mg per week, tailored to minimize virilization risks.
STORAGE & HANDLING
Store Bioniche Pharma injectable products in a cool, dry place protected from direct light exposure and excess heat. Do not refrigerate or freeze Bioniche Pharma products. Keep strictly out of reach and sight of children.